Clinical Trials Logo

Clinical Trial Summary

The two curative treatment modalities for patients with HNSCC - primary chemoradiation (CRT) or primary surgery (often combined with postoperative (C)RT) - are both associated with serious side effects for which reason further stratification, optimization and personalization of treatment is urgently needed. As novel quantitative image analyses are a promising tool for further risk stratification, the investigators training a three-dimensional Convolutional Neural Network on 18F-Fluorodesoxyglucose (FDG) positron emission tomography (PET) imaging and clinical / histopathological data of a multicentric, retrospective cohort of 1200 patients treated with primary CRT and 800 patients treated with primary surgery at Charité and cooperation institutes in order to predict individual treatment-specific outcomes and identify patients with excellent outcome after primary CRT or primary surgery or unfavorable outcome for both. The trained algorithm of the artificial intelligence will be validated in a prospective trial to see if predicted loco-regional control and recommended treatment strategies are reliable. In total 250 curative HNSCC patients, treated with CRT or primary surgery, will be enrolled on this prospective validation trial with observational character, while biomarker, clinical and FDG-PET data are collected from these patients and follow-up visits will be concluded.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05192655
Study type Observational
Source Charite University, Berlin, Germany
Contact Julian Weingärtner, Dr. med.
Phone 0030-450-657057
Email [email protected]
Status Recruiting
Phase
Start date December 1, 2021
Completion date December 1, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT02999087 - Randomized Trial of Avelumab-cetuximab-radiotherapy Versus SOCs in LA SCCHN (REACH) Phase 3
Recruiting NCT03292250 - Korean Cancer Study Group: Translational bIomarker Driven UMbrella Project for Head and Neck (TRIUMPH), Esophageal Squamous Cell Carcinoma- Part 1 (HNSCC)] Phase 2
Recruiting NCT04272333 - Intratumoral Microdosing of Motolimod in HNSCC Early Phase 1
Recruiting NCT04606940 - Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)
Recruiting NCT03356587 - A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy Phase 2
Recruiting NCT03719690 - Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy Phase 2
Completed NCT03367780 - Dose-Effect Relation of Salivary Gland Irradiation
Recruiting NCT04141449 - A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation Phase 2
Recruiting NCT04042935 - Alpha Lipoic Acid to Decrease Pain and Side Effects in Concurrent Treatment of HNSCC Phase 1
Recruiting NCT04157985 - Evaluation of the Length of Treatment With PD-1/PD-L1 Inhibitors in Patients With Advanced Solid Tumors Phase 3
Recruiting NCT04279509 - Selecting Chemotherapy With High-throughput Drug Screen Assay Using Patient Derived Organoids in Patients With Refractory Solid Tumours (SCORE) N/A
Recruiting NCT03652142 - Predictive Biomarkers for Response to Nivolumab in Head and Neck Squamous Cell Carcinoma
Recruiting NCT04354246 - COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies Phase 1
Recruiting NCT03082534 - Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma Phase 2
Active, not recruiting NCT03107182 - Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer Phase 2
Recruiting NCT04169074 - Immune Modulation by Abemaciclib in HNSCC. (AIM Trial) Phase 2
Not yet recruiting NCT04861467 - Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma Phase 2
Recruiting NCT03726775 - Trial Evaluating the Tolerance and Safety of Durvalumab - RT Combination for Treatment in SCCHN Phase 2
Terminated NCT03740100 - Single-arm Study With Bimiralisib in Patients With HNSCC Harboring NOTCH1 Loss of Function Mutations Phase 2
Recruiting NCT04722523 - A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer Phase 1